Unverified: No Public Evidence Backs the Claim That Apitegromab Preserved 55% More Lean Mass in a Tirzepatide Trial

A specific-sounding claim has been circulating that a clinical trial of 102 people over 24 weeks found apitegromab — a drug that blocks myostatin, a protein that limits muscle growth — helped people retain 55% more lean mass when combined with the popular weight-loss drug tirzepatide. The verdict: unverifiable. No confirmed public source backs these exact numbers.

Apitegromab is real, and the research behind it is legitimate. Scholar Rock, the company developing it, has registered trials on ClinicalTrials.gov exploring whether the drug can protect muscle during GLP-1-based weight loss. The science is plausible — GLP-1 drugs like tirzepatide do cause some muscle loss alongside fat loss, and a myostatin inhibitor could theoretically help.

But plausible science is not the same as proven results. Searches of major medical journals including the New England Journal of Medicine and JAMA turn up no published study matching the trial described. Scholar Rock's own press releases, reviewed through their investor relations page, do not confirm the specific figures of 102 participants, 24 weeks, or a 55% lean mass retention advantage.

The strongest version of this claim might be that Scholar Rock shared early or preliminary data at a conference or in an investor briefing that was then paraphrased, inflated, or stripped of important caveats as it spread online. Early-phase data is often incomplete, not yet peer-reviewed, and can look more impressive before full analysis. Without a confirmed source, these numbers should not be treated as established fact.

This kind of claim spreads fast because it sounds authoritative — specific numbers, a named drug, a real company. But precise-sounding figures can actually be a red flag. Real clinical results go through peer review before being cited as evidence. Until Scholar Rock publishes or formally presents verified data, treat this claim as unconfirmed.